Novel endocrine aspects of prostate cancer

Molecular and Cellular Endocrinology

Volumn 360, Issue 1-2, 2012, Pages 1-2

  Visakorpi, Tapio ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; DNA TOPOISOMERASE (ATP HYDROLYSING); DUTASTERIDE; FINASTERIDE; FLUTAMIDE; TRANSCRIPTION FACTOR ERG;

ANDROGEN RELEASE; ANTIANDROGEN THERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; CHROMOSOME REARRANGEMENT; DOUBLE STRANDED DNA BREAK; EDITORIAL; ENDOCRINE FUNCTION; ENVIRONMENTAL FACTOR; ERG GENE; FUSION GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE LOCATION; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; HEREDITY; HORMONE ACTION; HUMAN; MALIGNANT TRANSFORMATION; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BINDING; RISK REDUCTION; TESTOSTERONE BLOOD LEVEL; TMPRSS2 GENE; TUMOR GENE;

ANDROGENS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; MALE; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS;

EID: 84864022923     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.03.015     Document Type: Editorial

References (16)

1. Andriole G.L., Bostwick D.G., Brawley O.W., Gomella L.G., Marberger M., Montorsi F., Pettaway C.A., Tammela T.L., Teloken C., Tindall D.J., Somerville M.C., Wilson T.H., Fowler I.L., Rittmaster R.S. REDUCE Study Group. Effect of dutasteride on the risk of prostate cancer. N. Engl. J. Med. 2010, 362:1192-1202.
2. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
3. de bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., Chi K.N., Jones R.J., Goodman O.B., Saad F., Staffurth J.N., Mainwaring P., Harland S., Flaig T.W., Hutson T.E., Cheng T., Patterson H., Hainsworth J.D., Ryan C.J., Sternberg C.N., Ellard S.L., Fléchon A., Saleh M., Scholz M., Efstathiou E., Zivi A., Bianchini D., Loriot Y., Chieffo N., Kheoh T., Haqq C.M., Scher H.I. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 2011, 364:1995-2005. COU-AA-301 Investigators.
4. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer 2010, 46:765-781.
5. Haffner M.C., Aryee M.J., Toubaji A., Esopi D.M., Albadine R., Gurel B., Isaacs W.B., Bova G.S., Liu W., Xu J., Meeker A.K., Netto G., De Marzo A.M., Nelson W.G., Yegnasubramanian S. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat. Genet. 2010, 42:668-675.
6. Hu R., Dunn T.A., Wei S., Isharwal S., Veltri R.W., Humphreys E., Han M., Partin A.W., Vessella R.L., Isaacs W.B., Bova G.S., Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009, 69:16-22.
7. Huggins C., Hodges C.V. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941, 1:293-297.
8. Linja M.J., Savinainen K.J., Saramäki O.R., Tammela T.L., Vessella R.L., Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 2001, 61:3550-3555.
9. Montgomery R.B., Mostaghel E.A., Vessella R., Hess D.L., Kalhorn T.F., Higano C.S., True L.D., Nelson P.S. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008, 68:4447-4454.
10. Patel A.R., Klein E.A. Risk factors for prostate cancer. Nat. Clin. Pract. Urol. 2009, 6:87-95.
11. Scher H.I., Beer T.M., Higano C.S., Anand A., Taplin M.E., Efstathiou E., Rathkopf D., Shelkey J., Yu E.Y., Alumkal J., Hung D., Hirmand M., Seely L., Morris M.J., Danila D.C., Humm J., Larson S., Fleisher M., Sawyers C.L. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010, 375:1437-1446. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium, 2010.
12. Taplin M.E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., Ogata G.K., Keer H.N., Balk S.P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 1995, 332:1393-1398.
13. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., Lieber M.M., Cespedes R.D., Atkins J.N., Lippman S.M., Carlin S.M., Ryan A., Szczepanek C.M., Crowley J.J., Coltman C.A. The influence of finasteride on the development of prostate cancer. N. Engl. J. Med. 2003, 349:215-224.
14. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., Varambally S., Cao X., Tchinda J., Kuefer R., Lee C., Montie J.E., Shah R.B., Pienta K.J., Rubin M.A., Chinnaiyan A.M. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310:644-648.
15. Varghese J.S., Easton D.F. Genome-wide association studies in common cancers - what have we learnt?. Curr. Opin. Genet. Dev. 2010, 20:201-209.
16. Visakorpi T., Hyytinen E., Koivisto P., Tanner M., Keinänen R., Palmberg C., Palotie A., Tammela T., Isola J., Kallioniemi O.P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 1995, 9:401-406.